Merck Reports observational Data for Ribociclib in Chronic kidney disease

Merck today announced observational results for ribociclib in patients with chronic kidney disease. The study demonstrated that ribociclib achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of chronic kidney disease and support the continued development of ribociclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.